Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
3 "Radiotherapy"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Article image
Polo-like kinase 4 as a potential predictive biomarker of chemoradioresistance in locally advanced rectal cancer
Hyunseung Oh, Soon Gu Kim, Sung Uk Bae, Sang Jun Byun, Shin Kim, Jae-Ho Lee, Ilseon Hwang, Sun Young Kwon, Hye Won Lee
J Pathol Transl Med. 2022;56(1):40-47.   Published online November 16, 2021
DOI: https://doi.org/10.4132/jptm.2021.10.07
  • 4,307 View
  • 159 Download
AbstractAbstract PDFSupplementary Material
Background
Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase located in the centriole of the chromosome during the cell cycle. PLK4 overexpression has been described in a variety of many common human epithelial tumors. Conversely, PLK4 acts as a haploinsufficient tumor suppressor in some situations, highlighting the importance of strict regulation of PLK4 expression, activity, and function. Meanwhile, the importance of chemoradiation resistance in rectal cancer is being emphasized more than ever. We aimed to analyze PLK4 expression and the tumor regression grade (TRG) in patients with rectal cancer, treated with chemoradiotherapy (CRT).
Methods
A retrospective study was conducted on 102 patients with rectal cancer who received preoperative CRT. Immunohistochemistry for PLK4 in paraffin-embedded tissue was performed from the biopsy and surgical specimens.
Results
We found significant association between high expression of PLK4 and poor response to neoadjuvant CRT (according to both Mandard and The Korean Society of Pathologists TRG systems) in the pre-CRT specimens. Other clinicopathologic parameters did not reveal any correlation with PLK4 expression.
Conclusions
This study revealed an association between high expression of PLK4 in the pre-CRT specimens and TRG. Our results indicated that PLK4 could potentially be a new predictor for CRT effect in patients with rectal cancer.
Review
Radiotherapy Response in Microsatellite Instability Related Rectal Cancer
Joo-Shik Shin, Thein Ga Tut, Tao Yang, C. Soon Lee
Korean J Pathol. 2013;47(1):1-8.   Published online February 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.1
  • 10,815 View
  • 96 Download
  • 29 Crossref
AbstractAbstract PDF

Preoperative radiotherapy may improve the resectability and subsequent local control of rectal cancers. However, the extent of radiation induced regression in these tumours varies widely between individuals. To date no reliable predictive marker of radiation sensitivity in rectal cancer has been identified. At the cellular level, radiation injury initiates a complex molecular network of DNA damage response (DDR) pathways that leads to cell cycle arrest, attempts at re-constituting the damaged DNA and should this fail, then apoptosis. This review presents the details which suggest the roles of DNA mismatch repair proteins, the lack of which define a distinct subset of colorectal cancers with microsatellite instability (MSI), in the DDR pathways. Hence routine assessment of the MSI status in rectal cancers may potentially serve as a predictor of radiotherapy response, thereby improving patient stratification in the administration of this otherwise toxic treatment.

Citations

Citations to this article as recorded by  
  • Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer
    Sung Uk Bae, Hye Won Lee, Jee Young Park, Incheol Seo, Jae-Min Cho, Jin Young Kim, Ju Yup Lee, Yoo Jin Lee, Seong Kyu Baek, Nam Kyu Kim, Sang Jun Byun, Shin Kim
    Clinical and Translational Radiation Oncology.2025; 51: 100906.     CrossRef
  • Incidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands
    Eline G.M. van Geffen, Cornelis R.C. Hogewoning, Sanne-Marije J.A. Hazen, Tania C. Sluckin, Marilyne M. Lange, Petur Snaebjornsson, Regina G.H. Beets-Tan, Corrie A.M. Marijnen, Cornelis Verhoef, Myriam Chalabi, Pieter J. Tanis, Miranda Kusters, Tjeerd S.
    Clinical Colorectal Cancer.2024;[Epub]     CrossRef
  • Potential risks associated with the use of ionizing radiation for imaging and treatment of colorectal cancer in Lynch syndrome patients
    Mingzhu Sun, Jayne Moquet, Michele Ellender, Simon Bouffler, Christophe Badie, Rachel Baldwin-Cleland, Kevin Monahan, Andrew Latchford, David Lloyd, Susan Clark, Nicola A. Anyamene, Elizabeth Ainsbury, David Burling
    Familial Cancer.2023; 22(1): 61.     CrossRef
  • Not All Patients With Locally Advanced Rectal Cancer Benefit From Neoadjuvant Therapy
    Carolyn Chang, Jonathan T. Bliggenstorfer, Jessie Liu, Jennifer Shearer, Paul Dreher, Katherine Bingmer, Sharon L. Stein, Emily Steinhagen
    The American Surgeon™.2023; 89(11): 4327.     CrossRef
  • Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone
    Kemin Ni, Yixiang Zhan, Zhaoce Liu, Zhen Yuan, Shuyuan Wang, Xuan-zhu Zhao, Hangyu Ping, Yaohong Liu, Wanting Wang, Suying Yan, Ran Xin, Qiurong Han, Qinghuai Zhang, Guoxun Li, Xipeng Zhang, Guihua Wang, Zili Zhang, Hong Ma, Chunze Zhang
    BMC Cancer.2023;[Epub]     CrossRef
  • Rectal Cancer in Patients with Hereditary Nonpolyposis Colorectal Cancer Compared with Sporadic Cases: Response to Neoadjuvant Chemoradiation and Local Recurrence
    Khaled M Madbouly, Sameh Hany Emile, Yasmine Amr Issa
    Journal of the American College of Surgeons.2022; 234(5): 793.     CrossRef
  • Molecular Recognition and Quantification of MLH1, MSH2, MSH6, PMS2, and KRAS in Biological Samples
    Raluca-Ioana Stefan-van Staden, Ruxandra-Maria Ilie-Mihai, Maria Coros, Stela Pruneanu
    ECS Sensors Plus.2022; 1(3): 031606.     CrossRef
  • Magnetic Resonance Imaging Downstaging, Pathological Response, and Microsatellite Instability Status in Patients with Signet-Ring Cell Carcinoma Rectum Undergoing Preoperative Long-course Chemoradiation
    B. Rajkrishna, Saikat Das, Dipti Masih, Tharani Putta, Rajat Raghunath, Thomas Samuel Ram
    Current Medical Issues.2022; 20(3): 154.     CrossRef
  • Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients
    Aylin Alkan, Tobias Hofving, Eva Angenete, Ulf Yrlid
    Biomarker Research.2021;[Epub]     CrossRef
  • Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer
    Shaakir Hasan, Paul Renz, Rodney E. Wegner, Gene Finley, Moses Raj, Dulabh Monga, James McCormick, Alexander Kirichenko
    Annals of Surgery.2020; 271(4): 716.     CrossRef
  • Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm
    Éanna J. Ryan, Ben Creavin, Kieran Sheahan
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer
    Shu-Biao Ye, Yi-Kan Cheng, Lin Zhang, Yi-Feng Zou, Ping Chen, Yan-Hong Deng, Yan Huang, Jian-Hong Peng, Xiao-Jian Wu, Ping Lan
    npj Precision Oncology.2020;[Epub]     CrossRef
  • Implication of expression of MMR proteins and clinicopathological characteristics in gastric cancer
    Renu Verma, Puja Sakhuja, Ritu Srivastava, Prakash Chand Sharma
    Asia-Pacific Journal of Oncology.2020; : 1.     CrossRef
  • Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
    Andrea Cercek, Gustavo Dos Santos Fernandes, Campbell S. Roxburgh, Karuna Ganesh, Shu Ng, Francisco Sanchez-Vega, Rona Yaeger, Neil H. Segal, Diane L. Reidy-Lagunes, Anna M. Varghese, Arnold Markowitz, Chao Wu, Bryan Szeglin, Charles-Etienne Gabriel Sauvé
    Clinical Cancer Research.2020; 26(13): 3271.     CrossRef
  • The Mismatch Repair System (MMR) in Head and Neck Carcinogenesis and Its Role in Modulating the Response to Immunotherapy: A Critical Review
    Maria Cilona, Luca Giovanni Locatello, Luca Novelli, Oreste Gallo
    Cancers.2020; 12(10): 3006.     CrossRef
  • Genetics of rectal cancer and novel therapies: primer for radiologists
    Sebastian Mondaca, Rona Yaeger
    Abdominal Radiology.2019; 44(11): 3743.     CrossRef
  • Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer
    Casper Reijnen, Heidi V.N. Küsters-Vandevelde, Clemens F. Prinsen, Leon F.A.G. Massuger, Marc P.M.L. Snijders, Stefan Kommoss, Sara Y. Brucker, Janice S. Kwon, Jessica N. McAlpine, Johanna M.A. Pijnenborg
    Gynecologic Oncology.2019; 154(1): 124.     CrossRef
  • Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
    Nicolas Meillan, Dewi Vernerey, Jérémie H. Lefèvre, Gilles Manceau, Magali Svrcek, Jeremy Augustin, Jean-François Fléjou, Olivier Lascols, Jean-Marc Simon, Romain Cohen, Philippe Maingon, Jean-Baptiste Bachet, Florence Huguet
    International Journal of Radiation Oncology*Biology*Physics.2019; 105(4): 824.     CrossRef
  • Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients
    Sally M. Shalaby, Amal S. El-Shal, Lobna A. Abdelaziz, Eman Abd-Elbary, Mostafa M. Khairy
    Gene.2018; 644: 66.     CrossRef
  • RBBP6 increases radioresistance and serves as a therapeutic target for preoperative radiotherapy in colorectal cancer
    Chao Xiao, Yupeng Wang, Miao Zheng, Jian Chen, Guohe Song, Zhijie Zhou, Chongzhi Zhou, Xing Sun, Lin Zhong, Erxun Ding, Yi Zhang, Liu Yang, Gang Wu, Shifeng Xu, Hong Zhang, Xiaoliang Wang
    Cancer Science.2018; 109(4): 1075.     CrossRef
  • Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K)
    Stefan Eder, Annette Arndt, Andreas Lamkowski, Wassiliki Daskalaki, Alexis Rump, Markus Priller, Felicitas Genze, Eva Wardelmann, Matthias Port, Konrad Steinestel
    Cancer Letters.2017; 385: 160.     CrossRef
  • The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing
    E. Ryan, K. Sheahan, B. Creavin, H.M. Mohan, D.C. Winter
    Critical Reviews in Oncology/Hematology.2017; 116: 38.     CrossRef
  • Exploration of Mutation and DNA Methylation of Polo-Like Kinase 1 (PLK1) in Colorectal Cancer
    Wayne Ng, Joo-Shik Shin, Bin Wang, Cheok Soon Lee
    Open Journal of Pathology.2017; 07(03): 45.     CrossRef
  • Expression of Mismatch Repair Proteins in Early and Advanced Gastric Cancer in Poland
    Katarzyna Karpińska-Kaczmarczyk, Magdalena Lewandowska, Małgorzata Ławniczak, Andrzej Białek, Elżbieta Urasińska
    Medical Science Monitor.2016; 22: 2886.     CrossRef
  • DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics
    Nicole de Rosa, Miguel A. Rodriguez-Bigas, George J. Chang, Jula Veerapong, Ester Borras, Sunil Krishnan, Brian Bednarski, Craig A. Messick, John M. Skibber, Barry W. Feig, Patrick M. Lynch, Eduardo Vilar, Y. Nancy You
    Journal of Clinical Oncology.2016; 34(25): 3039.     CrossRef
  • miRNA-148b regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1
    Guangsheng Zhai, Gaozhong Li, Bo Xu, Tongfu Jia, Yinping Sun, Jianbo Zheng, Jianbin Li
    Bioscience Reports.2016;[Epub]     CrossRef
  • Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    S.H. Lim, W. Chua, C. Henderson, W. Ng, J.-S. Shin, L. Chantrill, R. Asghari, C.S. Lee, K.J. Spring, P. de Souza
    Critical Reviews in Oncology/Hematology.2015; 96(1): 67.     CrossRef
  • Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers
    Ruth Exner, Walter Pulverer, Martina Diem, Lisa Spaller, Laura Woltering, Martin Schreiber, Brigitte Wolf, Markus Sonntagbauer, Fabian Schröder, Judith Stift, Fritz Wrba, Michael Bergmann, Andreas Weinhäusel, Gerda Egger
    British Journal of Cancer.2015; 113(7): 1035.     CrossRef
  • Study of Liver Transplant Rejection in Alcoholism-Induced Cirrhosis
    J. Tinoco González, C. Bernal Bellido, G. Jimenez Riera, V. Camacho Marente, L.M. Marín Gómez, G. Suárez Artacho, J.M. Álamo Martínez, J. Serrano Díez-Canedo, R.J. Padillo Ruíz, M.A. Gómez Bravo
    Transplantation Proceedings.2013; 45(10): 3650.     CrossRef
Original Article
The Expression of Hypoxia Inducible Factor-1alpha and Its Correlation with the Expressions of Cyclin A1 and Cyclin B1 and the Clinicopathologic Factors of Uterine Cervical Carcinoma.
Ju Yeon Pyo, Jae Ho Cho, Hyunki Kim, Jong Pil Park, Young Tae Kim, Nam Hoon Cho
Korean J Pathol. 2009;43(1):13-19.
DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.1.13
  • 2,976 View
  • 32 Download
AbstractAbstract PDF
BACKGROUND
Hypoxia inducible factor-1alpha(HIF-1alpha) is a transcription factor for various target genes that are involved in adapting cells to hypoxia. It promotes cell proliferation and survival via modulation of such cell cycle regulators such as cyclin A1 and cyclin B1 in response to hypoxia. This is associated with local failure of radiotherapy, which renders a poor prognosis for cervical carcinoma.
METHODS
Using the tissue histologic sections and a tissue microarray of the archived biopsy and surgical specimens of uterine cervical carcinoma from 57 patients who were treated with radiation therapy alone, we performed immunohistochemical staining for HIF-1alpha and cyclin A1 and B1 to evaluate the correlations between the expressions of these proteins in tumors and the clinicopathologic parameters associated with the prognosis.
RESULTS
The large tumor cell nests and invasive front margins of the tumors showed comparatively intense immunoreactivity of HIF-1alpha. There was no significant correlation between the HIF-1alpha, cyclin A1 and cyclin B1 expressions and the clinicopathologic factors.
CONCLUSIONS
The HIF-1alpha expression showed marked intra-tumoral heterogeneity. The HIF-1alpha expression is neither a powerful predictor of resistance to radiotherapy nor is it a poor prognostic marker in cervical carcinoma patients who are treated with radiotherapy. The expressions of cyclin A1 and cyclin B1 are neither independently associated with the response of radiation therapy nor are they associated with the prognostic parameters of uterine cervical carcinoma.

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP